Regentis Biomaterials is a regenerative medicine company that develops biodegradable hydrogel implants to repair and regenerate damaged orthopedic tissue, specifically focused on focal knee cartilage injuries. Their lead product, GelrinC, is a cell-free, "off-the-shelf" implant made from a proprietary matrix of polyethylene glycol diacrylate and denatured fibrinoge
Possible catalysts: annual general shareholder meeting at 8:00AM EST
2. Pivotal U.S. Phase III Trial Progress
Regentis is targeting a massive U.S. addressable population of over 470,000 knee cartilage repair cases annually.
**The Milestone:** Its pivotal U.S. FDA investigational device exemption (IDE) Phase III study has **surpassed the 50% enrollment threshold**. To accelerate the back half of the trial, the company recently expanded its network to include major high-volume academic orthopedic centers like NYU Langone, Ohio State Wexner, and Rush University Medical Center.
**What to watch:** Official press releases during the meeting today confirming the completion of full patient recruitment or any early safety data readouts.
4. Implementation of the New High-Yield Manufacturing Process
**The Milestone:** Earlier this year, Regentis patented a proprietary, solvent-free manufacturing process that reportedly **increases GelrinC production yields by 400%**.
**What to watch:** Updates regarding the validation and scaling of this process to support commercial rollout volumes later this year.
Keep in mind Institutions bought in at 3.5, so that’s essentially the price floor.
Today’s borrow rate: %697.54
Short interest: 33%
Days to cover: 3.72
Short shares available: 75,000
Total public float: 3.7M
(4Million of the 7M are locked up until September)
Let me know what yall think!